# Turning Point Therapeutics

Source: https://onco.cc/companies/turning-point-therapeutics/  
OnCo record `turning-point-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Turning Point Therapeutics developed repotrectinib, a pill aimed at lung cancers and other tumours driven by ROS1 or NTRK gene changes. Bristol Myers Squibb bought the company in 2022.

## Summary

Turning Point Therapeutics, Inc. (formerly Nasdaq: TPTX), of San Diego, was a clinical-stage precision oncology company. Its lead asset, repotrectinib, is a tyrosine kinase inhibitor aimed at the ROS1 and NTRK cancer drivers in non-small cell lung cancer and other advanced solid tumours. Bristol Myers Squibb agreed on 3 June 2022 to buy Turning Point for USD 76 per share in cash, an equity value of USD 4.1 billion, and the merger was completed on 17 August 2022.

## Fields

- Kind: Company
- Last checked: 2026-11-03
- Also known as: Turning Point Therapeutics, Inc.; NASDAQ:TPTX
- HQ: San Diego, CA
- Type: biotech

## Notes

- Completion on 17 August 2022 is from Turning Point's 8-K of that date. No website or founding year is recorded.

## Sources

- Bristol Myers Squibb to acquire Turning Point Therapeutics (8-K exhibit 99.1, 3 June 2022): https://www.sec.gov/Archives/edgar/data/1595893/000119312522166796/d344596dex991.htm
- Turning Point investor messages: USD 4.1 billion equity value (Schedule 14D-9C exhibit 99.2): https://www.sec.gov/Archives/edgar/data/1595893/000119312522166807/d337235dex992.htm
- Form 8-K: completion of the merger (17 August 2022): https://www.sec.gov/Archives/edgar/data/1595893/000114036122029961/brhc10040812_8k.htm

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [NTRK](https://onco.cc/targets/ntrk/), [ROS1](https://onco.cc/targets/ros1/)
- drugs: [Repotrectinib](https://onco.cc/drugs/repotrectinib/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/turning-point-therapeutics.json